

## SIERRA LEONE Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Sierra Leone						
<b>2. Grant number:</b> 09-SLE-8b-Y; 1821-SLE-12d-X						
<b>3. Date of Decision Letter:</b> 22 December 2017						
<b>4. Date of the Partnership Framework Agreement:</b> 10 March 2013						
<b>5. Programme title:</b> New Vaccine Support (NVS), Pneumococcal Routine						
<b>6. Vaccine type:</b> Pneumococcal						
<b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV13), 4 dose(s) per vial , LIQUID						
<b>8. Programme duration<sup>1</sup>:</b> 2010 - 2021						
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)						
	2010-2017	2018	2019	2020	2021	Total <sup>2</sup>
Programme Budget (US\$)	23,970,527 <sup>3</sup>	3,086,000	3,231,000	3,456,500	3,567,500	37,311,527
<b>10. Vaccine introduction grant (in US\$)</b>						
<b>11. Gavi Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>						
Type of supplies to be purchased with Gavi funds in each year	2010-2017		2018			
Number of Pneumococcal vaccines doses			919,000			
Annual Amounts (US\$)	23,970,527 <sup>5</sup>		3,086,000			

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

For information and reference, the related Injection Safety Devices to be purchased under Gavi funds for 2017 shall be included in a separate Decision Letter (Grant Number 17-SLE-32a-X; 18-SLE-32a-X; 19-SLE-32a-X; 20-SLE-32a-X; 21-SLE-32a-X):

<b>New Vaccine Support (NVS), Pneumococcal (PCV13), 1 dose(s) per vial LIQUID,Routine</b>	<b>2018</b>
Number of AD syringes	977,700
Number of re-constitution syringes	
Number of safety boxes	10,775
Annual Amounts for injection safety devices for Vaccine (US\$)	44,500

**12. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

**13. Self-procurement:** Not applicable.

**14. Co-financing obligations:** Reference code: 1821-SLE-12d-X-C  
According to the co-financing policy, the Country falls within the group Initial self-financing.  
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2018	2019	2020	2021
Number of vaccine doses	64,200	64,600	66,600	68,800
Value of vaccine doses (US\$)	195,461			
Total co-financing payments (US\$) (including freight)	197,000	198,000	204,000	211,000

**15. Operational support for campaigns:** Not applicable

<b>16. Additional reporting requirements:</b>	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
<b>17. Financial clarifications:</b> Not applicable	
<b>18. Other conditions:</b> Not applicable	

On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes

22 December 2017

## SIERRA LEONE Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Sierra Leone						
<b>2. Grant number:</b> 1821-SLE-04c-X						
<b>3. Date of Decision Letter:</b> 22 December 2017						
<b>4. Date of the Partnership Framework Agreement:</b> 10 March 2013						
<b>5. Programme title:</b> New Vaccine Support (NVS), Pentavalent Routine						
<b>6. Vaccine type:</b> Pentavalent						
<b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 10 dose(s) per vial, LIQUID						
<b>8. Programme duration<sup>1</sup>:</b> 2007 - 2021						
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)						
	2007-2017	2018	2019	2020	2021	Total <sup>2</sup>
Programme Budget (US\$)	17,104,449 <sup>3</sup>	561,500	490,500	625,500	624,500	19,406,449
<b>10. Vaccine introduction grant (in US\$) / Product switch grant:</b> Not applicable						
<b>11. Gavi Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>						
Type of supplies to be purchased with Gavi funds in each year	2007-2017		2018			
Number of Pentavalent vaccines doses			722,500			
Annual Amounts (US\$)	17,104,449 <sup>5</sup>		561,500			

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

For information and reference, the related Injection Safety Devices to be purchased under Gavi funds for 2017 shall be included in a separate Decision Letter (Grant Number 17-SLE-32a-X; 18-SLE-32a-X; 19-SLE-32a-X; 20-SLE-32a-X; 21-SLE-32a-X):

<b>New Vaccine Support (NVS), DTP-HepB-Hib, 10 dose(s) per vial, LIQUID,Routine</b>	<b>2018</b>
Number of AD syringes	966,500
Number of safety boxes	10,650
Annual Amounts for injection safety devices for Vaccine (US\$)	44,000

**12. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

**13. Self-procurement:** Not applicable

**14. Co-financing obligations:** Reference code: 1821-SLE-04c-X-C  
According to the co-financing policy, the Country falls within the group Initial self-financing.  
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2018	2019	2020	2021
Number of vaccine doses	250,500	274,000	349,500	349,000
Number of AD syringes				
Number of re-constitution syringes				
Number of safety boxes				
Value of vaccine doses (US\$)	187,874			
Total co-financing payments (US\$) (including freight)	195,000	193,500	247,000	246,500

<b>15. Operational support for campaigns:</b> Not applicable	
<b>16. Additional reporting requirements:</b>	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
<b>17. Financial clarifications:</b> Not applicable	
<b>18. Other conditions:</b> Not applicable	

On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes

22 December 2017

## SIERRA LEONE Support for Rotavirus Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Sierra Leone						
<b>2. Grant number:</b> 12-SLE-08a-Y; 1821-SLE-13b-X						
<b>3. Date of Decision Letter:</b> 22 December 2017						
<b>4. Date of the Partnership Framework Agreement:</b> 10 March 2013						
<b>5. Programme title:</b> New Vaccine Support (NVS), Rotavirus Routine						
<b>6. Vaccine type:</b> Rotavirus						
<b>7. Requested product presentation and formulation of vaccine:</b> Rotavirus, 2 dose(s) schedule						
<b>8. Programme duration<sup>1</sup>:</b> 2012 - 2021						
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)						
	2012-2017	2018	2019	2020	2021	Total <sup>2</sup>
Programme Budget (US\$)	4,085,725 <sup>3</sup>	949,500	1,115,500	1,160,500	1,197,000	8,508,225
<b>10. Vaccine introduction grant (in US\$):</b> US\$ 193,500 disbursed on 6 May 2014						
<b>11. Gavi Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>						
Type of supplies to be purchased with Gavi funds in each year	2012-2017		2018			
Number of Rotavirus vaccines doses			456,000			
Annual Amounts (US\$)	4,085,725 <sup>5</sup>		949,500			

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.																								
<b>13. Self-procurement:</b> Not applicable																								
<p><b>14. Co-financing obligations:</b> Reference code: 1821-SLE-13b-X-C According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2018</th> <th>2019</th> <th>2020</th> <th>2021</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>49,500</td> <td>58,500</td> <td>60,000</td> <td>61,500</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>97,895</td> <td></td> <td></td> <td></td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>101,500</td> <td>119,000</td> <td>124,000</td> <td>127,500</td> </tr> </tbody> </table>					Type of supplies to be purchased with Country funds in each year	2018	2019	2020	2021	Number of vaccine doses	49,500	58,500	60,000	61,500	Value of vaccine doses (US\$)	97,895				Total co-financing payments (US\$) (including freight)	101,500	119,000	124,000	127,500
Type of supplies to be purchased with Country funds in each year	2018	2019	2020	2021																				
Number of vaccine doses	49,500	58,500	60,000	61,500																				
Value of vaccine doses (US\$)	97,895																							
Total co-financing payments (US\$) (including freight)	101,500	119,000	124,000	127,500																				
<b>15. Operational support for campaigns:</b> Not applicable																								
<b>16. Additional reporting requirements:</b>																								
Reports and other information				Due dates																				
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.				15 May 2018																				
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.				To be agreed with Secretariat																				
<b>17. Financial clarifications:</b> Not applicable																								
<b>18. Other conditions:</b> Not applicable																								



On behalf of Gavi

*Hind A. Khatib*

Hind Khatib-Othman  
Managing Director, Country Programmes

22 December 2017

## SIERRA LEONE Support for Yellow Fever Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Sierra Leone						
<b>2. Grant number:</b> 1821-SLE-06b-X						
<b>3. Date of Decision Letter:</b> 22 December 2017						
<b>4. Date of the Partnership Framework Agreement:</b> 10 March 2013						
<b>5. Programme title:</b> NVS, Yellow Fever Routine						
<b>6. Vaccine type:</b> Yellow Fever						
<b>7. Requested product presentation and formulation of vaccine:</b> Yellow Fever, 10 dose(s) per vial, LYOPHILISED						
<b>8. Programme duration<sup>1</sup>:</b> 2003 - 2021						
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)						
	2003-2017	2018	2019	2020	2021	Total <sup>2</sup>
Programme Budget (US\$)	2,761,452 <sup>3</sup>	326,000	296,000	311,000	321,000	4,015,452
<b>10. Vaccine introduction grant (in US\$):</b> 100,000 disbursed on 17.10.2002						
<b>11. Gavi Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable): <sup>4</sup>						
Type of supplies to be purchased with Gavi funds in each year	2003-2017		2018			
Number of Yellow Fever vaccines doses			283,300			
Annual Amounts (US\$)	2,761,452 <sup>5</sup>		326,000			

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

For information and reference, the related Injection Safety Devices to be purchased under Gavi funds for 2017 shall be included in a separate Decision Letter (Grant Number 17-SLE-32a-X; 18-SLE-32a-X; 19-SLE-32a-X; 20-SLE-32a-X; 21-SLE-32a-X):

<b>New Vaccine Support (NVS), Yellow Fever, 10 dose(s) per vial, LYOPHILISED,Routine</b>	<b>2018</b>
Number of AD syringes	341,800
Number of re-constitution syringes	37,800
Number of safety boxes	4,175
Annual Amounts for injection safety devices for Vaccine (US\$)	17,500

**12. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

**13. Self-procurement:** Not applicable

**14. Co-financing obligations: Reference code:** 1821-SLE-06b-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2018	2019	2020	2021
Number of vaccine doses	59,700	54,200	56,900	58,700
Value of vaccine doses (US\$)	63,826			
Total co-financing payments (US\$) (including freight)	69,000	62,500	65,500	67,500

**15. Operational support for campaigns:** Not applicable

<b>16. Additional reporting requirements:</b>	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
<b>17. Financial clarifications:</b> Not applicable	
<b>18. Other conditions:</b> There is currently a global shortage in the supply of yellow fever vaccines. The number of doses and presentation are subject to availability. Gavi will inform the Government as soon as possible of any changes in doses and/or presentation from what has been communicated to the Sierra Leone.	

On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes

22 December 2017